When immune cells switch sides: unstable T cells drive gum disease bone loss

Periodontitis, the chronic inflammatory disease that erodes the gums and the bone holding teeth in place, has long been blamed on bacteria. But a comprehensive new review published in Experimental & Molecular Medicine argues that the real culprit behind the destruction is not the microbes themselves — it is our own immune system, and specifically the startling instability of CD4+ T helper cells that are supposed to keep inflammation in check. The review, authored by Yun-Ji Lim and Tae Sung Kim of Pusan National University, shifts the scientific focus away from static categories of immune cells and toward their dynamic, shape-shifting behavior inside inflamed gum tissue.

The central argument is provocative: periodontitis should be understood not as a bacterial infection with an immune side effect, but as an immunopathological condition rooted in impaired immune homeostasis. While a dysbiotic microbiome — dominated by organisms such as Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, and Aggregatibacter actinomycetemcomitans — initiates the disease, the sustained destruction of connective tissue and alveolar bone is driven primarily by dysregulated host immune responses rather than direct bacterial toxicity. Environmental factors like smoking and stress compound the problem, but the tissue damage ultimately flows from chronic activation of inflammatory and osteoclastogenic networks within the periodontal microenvironment.

At the heart of this network are CD4+ T cells, which upon activation by antigen-presenting cells differentiate into specialized subsets: Th1, Th2, Th9, Th17, Th22, and regulatory T (Treg) cells. Each subset carries a distinct transcription factor and cytokine signature. For decades, researchers interpreted periodontal disease through the simplified Th1–Th2 paradigm, in which Th1 responses were cast as pro-inflammatory destroyers and Th2 responses as protective regulators. The new review dismantles that dichotomy. Th1 and Th2 cytokines are simultaneously detected in periodontal lesions, and their relative dominance fluctuates with disease stage, microbial burden, and the local cytokine milieu — evidence that the disease is not governed by any single, unidirectional T helper response.

The Th1 compartment illustrates this complexity. Driven by signals such as bacterial lipopolysaccharide and the cytokine IL-12, Th1 cells produce interferon-γ (IFNγ), which activates macrophages and amplifies pro-inflammatory signaling. Patients with periodontitis show elevated proportions of circulating and local Th1 cells and increased IFNγ expression compared with healthy controls. Yet IFNγ plays a genuinely context-dependent role: some evidence shows it can directly suppress osteoclast differentiation in vitro, potentially protecting against bone loss, while other studies link Th1-biased responses to increased inflammatory bone resorption. The net effect depends on the balance between antimicrobial defense, inflammatory amplification, and regulation of bone remodeling.

A parallel player, the cytokine IL-18, adds another layer to the Th1 story. Originally identified as an IFNγ-inducing factor, IL-18 is consistently elevated in the serum, saliva, and gingival crevicular fluid of periodontitis patients. It acts synergistically with IL-12 to sustain IFNγ production, and it may also directly participate in tissue destruction: IL-18 reportedly stimulates the activation of matrix metalloproteinases, enzymes that degrade the extracellular matrix, driving inflammatory bone loss after oral infection with P. gingivalis. The IL-18–Th1 axis, the review suggests, may be an important immunological link connecting adaptive immunity to alveolar bone destruction.

On the regulatory side, Th2 cells — defined by the transcription factor GATA3 and secretion of IL-4 and IL-13 — appear to restrain rather than fuel the disease. IL-4 can inhibit expression of key pro-inflammatory cytokines including IL-1, TNFα, and IL-6, and concentrations of IL-4 in gingival crevicular fluid are notably lower at periodontitis sites than in healthy gingiva, suggesting an association with inflammation resolution. IL-13, meanwhile, can upregulate transforming growth factor-β and downregulate the collagen-degrading enzyme MMP1 in gingival fibroblasts. The alarmin IL-33, released from gingival epithelial cells, further shapes a Th2-skewed microenvironment — though it too is double-edged, with some studies showing it can amplify early inflammatory responses and exacerbate bone loss depending on whether it is released in controlled or necrotic contexts.

The most dramatic character in this story, however, is the Th17 cell. Defined by the master transcription factor RORγt and production of IL-17A, IL-17F, IL-21, and IL-22, Th17 cells have been established as central pathogenic drivers of inflammatory bone loss. Elevated levels of RORC2 and IL-17A are documented in periodontal lesions, localized within the lamina propria, and their expression positively correlates with clinical attachment loss and bone destruction. Mechanistically, IL-17 acts on osteoblasts and periodontal ligament cells to upregulate RANKL — the key osteoclast-promoting signal — while downregulating its decoy receptor osteoprotegerin, tipping the RANKL–OPG balance toward resorption. IL-17 also recruits neutrophils via chemokines such as CXCL1 and CXCL2, and excessive neutrophil accumulation produces matrix metalloproteinases, reactive oxygen species, and neutrophil extracellular traps that compound tissue breakdown. The cytokine IL-23, produced in response to dysbiotic microbial stimulation, is critical for stabilizing and amplifying these pathogenic Th17 responses. Yet even IL-17 is not simply villainous: at controlled physiological levels it maintains mucosal barrier homeostasis and clears extracellular microbes without destructive inflammation.

The review’s most striking claim concerns what happens when the system’s own brakes fail. Treg cells, characterized by Foxp3 expression, are supposed to suppress excessive inflammation through TGFβ, IL-10, and IL-35, restraining Th1, Th17, and B cell responses and shifting the RANKL–OPG balance toward a bone-protective state. Experimental models support this: expanding or transferring Treg cells reduces inflammatory cytokine production and alveolar bone loss, while depleting them worsens disease. But under chronic inflammatory conditions, Treg cells undergo functional instability. Persistent IL-6–STAT3 signaling destabilizes Foxp3 expression by altering methylation of the TSDR regulatory region, predisposing Treg cells to convert into IL-17-producing ex-Treg cells. These hybrid populations — IL-17+ Tregs and Foxp3+ Th17 cells — display markedly enhanced osteoclastogenic potential compared with conventional Th17 cells and are implicated as key contributors to pathological bone resorption. In other words, the immune system’s peacekeepers are being conscripted into the destruction they were meant to prevent.

Adding a further dimension, recent spatial transcriptomic and single-cell studies reveal that the periodontal immune landscape is highly organized. Periodontitis lesions contain immune cell aggregates resembling tertiary lymphoid structures — localized hubs that sustain antigen presentation, T cell activation, and B cell maturation directly within chronically inflamed gingival tissue. The close spatial proximity of antigen-presenting cells, T helper cells, and B cell-rich compartments may facilitate sustained exposure to IL-6 and IL-23, promoting Th17 expansion and Treg instability while stabilizing chronic inflammatory circuits that resist systemic immune regulation. Along the Th17–Tfh axis, Th17 cells can even acquire T follicular helper-like features during chronic inflammation, reshaping local humoral responses, though the functional consequences remain incompletely understood.

The therapeutic implications are profound. If periodontitis reflects immune imbalance and phenotypic instability rather than the dominance of a single lineage, then selectively suppressing individual cytokines or discrete T cell subsets may be insufficient as long as the underlying dysregulation persists. The review argues that future interventions should instead reinforce regulatory stability, preserve protective T cell phenotypes, and restore a balanced cytokine environment supporting controlled host–microbe equilibrium. Emerging subsets such as Th9 and Th22 cells — whose contributions remain largely correlative and require loss-of-function studies to resolve — may offer additional targets. Ultimately, the authors contend, understanding T cell plasticity and immune adaptation within the periodontal microenvironment will be essential for designing next-generation precision host-modulatory therapies: treatments that restore durable immune homeostasis, prevent pathological osteoclastogenesis, and protect the bone that anchors our teeth — all without compromising the antimicrobial defenses we cannot afford to lose.

Subject of Research: T helper cell plasticity and Th17–Treg instability in the immunopathogenesis of periodontitis

Article Title: The dynamic landscape of T helper cell plasticity and Th17–Treg instability in periodontitis

Article References: Lim, Y.-J., & Kim, T. S. (2026). The dynamic landscape of T helper cell plasticity and Th17–Treg instability in periodontitis. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01847-4

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01847-4

Keywords: periodontitis, T helper cells, Th17, Treg cells, immune plasticity, IL-17, IL-23, osteoclastogenesis, alveolar bone loss, Foxp3, oral mucosal immunity, cytokines